Bridgebio Pharma, Inc. · NASDAQ:BBIO
HALVORSEN OLE ANDREAS reported a 9.70% stake in Bridgebio Pharma, Inc. (Schedule 13D/A)
Event Aug 14, 2025 · Filed Aug 14, 2025
HALVORSEN OLE ANDREAS reported a 9.70% stake in Bridgebio Pharma, Inc., 18,602,920 shares, with active intent on Aug 14, 2025. Filed Aug 14, 2025 (Schedule 13D/A).
- Stake
- 9.70%
- Shares
- 18,602,920
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| VIKING GLOBAL INVESTORS LP | 9.30% | 17,780,183 |
| VIKING GLOBAL PERFORMANCE LLC | 0.10% | 213,000 |
| Viking Global Equities II LP | 0% | 4,260 |
| Viking Global Equities Master Ltd. | 0.10% | 208,740 |
| Viking Long Fund GP LLC | 0.04% | 77,532 |
| Viking Long Fund Master Ltd. | 0.04% | 77,532 |
| Viking Global Opportunities Parent GP LLC | 9.10% | 17,489,651 |
| Viking Global Opportunities GP LLC | 9.10% | 17,489,651 |
| Viking Global Opportunities Portfolio GP LLC | 9.10% | 17,489,651 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 9.10% | 17,456,849 |
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0.02% | 32,802 |
| HALVORSEN OLE ANDREAS | 9.70% | 18,602,920 |
| Ott David C. | 9.70% | 18,602,920 |
| Shabet Rose Sharon | 9.70% | 18,602,920 |